Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

intechbiopharm.com

Stage

IPO | IPO

Date of IPO

3/28/2018

Market Cap

5.03B

About Intech Biopharm

Provider of drugs for obstructive airway diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD).

Intech Biopharm Headquarters Location

358 Ruiguang Road No. 36, 3rd Floor

Taipei, 11492,

Taiwan

886 2 77218877

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Intech Biopharm News

Intech testing new asthma inhaler with eye on US market

Nov 1, 2021

Intech testing new asthma inhaler with eye on US market By Kao Shih-ching / Staff reporter Intech Biopharm Corp (益得生技) has started testing the effects of a metered-dose inhaler generic of Teva Pharmaceutical Industries Ltd’s ProAir, and expects to gain marketing approval by 2023, it said yesterday. The company, which developed SYN011 to treat acute asthma, received approval from the US Food and Drug Administration in August to study the biochemical and physiological effects of the drug in a phase 3 clinical trial, Intech spokesperson Hugues Hung (洪堯國) told the Taipei Times. The company has recruited about 200 participants with asthma for the test, dividing them into control and experiment groups to receive a placebo, a brand name drug and SYN011, to determine whether SYN001’s efficacy is comparable to that of a brand name drug, Hung said. Intech Biopharm Corp chairman Peter Lin is pictured at the Taipei Exchange on March 1, 2018. Photo: CNA “We have to give participants some food containing allergens that can trigger asthma symptoms. We will see how the inhaler relieves the symptoms,” Hung said. The study is to finish by the end of next year, and Intech plans to apply to the US agency for marketing approval in the first quarter of 2023, he said. Intech is optimistic about the metered-dose inhalers market in the US, where the health regulator has become more open to generics amid the COVID-19 pandemic, he said. Prior to the pandemic, the agency never approved generic versions of metered-dose inhalers, although some applicants had completed trials, Hung said. As the pressurized metered-dose inhalers could be used to help relieve respiratory symptoms of people with COVID-19, the US regulator last year became more open, granting approvals to India-based Cipla Ltd and Lupin Ltd, which offer generic versions of Merck Sharp & Dohme Ltd’s (MSD) Proventil and Teva’s ProAir respectively, he said. Last year, Cipla sold about 3 million inhalers and Lupin sold 1 million at lower prices than those of brand names, or at a discount of between 50 and 60 percent, Hung said. Sales of MSD’s and Teva’s drugs were not affected by the generic versions, and they even raised their prices, suggesting there is a growing demand for the drug in the market, he said. Intech expects to be the latest supplier of metered-dose inhalers using salbutamol as the main ingredient, which is used to relieve symptoms of asthma, after GlaxoSmithKline PLC, MSD, Teva and the two Indian firms, Hung said. “With this market position, we will likely gain a market share of 10 to 20 percent,” he said. More than 64 million metered-dose inhalers using salbutamol were sold in the US last year, Hung said, adding that a larger market share would help boost Intech’s revenue. Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

Intech Biopharm Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Intech Biopharm Rank

  • Where is Intech Biopharm's headquarters?

    Intech Biopharm's headquarters is located at 358 Ruiguang Road, Taipei.

  • What is Intech Biopharm's latest funding round?

    Intech Biopharm's latest funding round is IPO.

  • Who are the investors of Intech Biopharm?

    Investors of Intech Biopharm include Harbinger Venture Management and TaiAn Technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.